Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital (“Vector”), a leading private equity firm specializing in transformational investments in established technology businesses, today announced it has ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

TORONTO, Jan. 22, 2026 /CNW/ - Agentiiv – a pioneer in enterprise-grade, agentic AI systems in Canada – today announced a technology partnership with the Vector Institute. As a Vector technology ...

Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

FOXO Technologies Inc. announced a non-binding agreement to acquire Vector Biosource Inc., a provider of biospecimen sourcing in the biotech and pharmaceutical sectors, with expected revenue of ...